Quick Takeaways
- RCKT - ROCKET PHARMACEUTICALS, INC. has 24 insiders with reported activity on this page.
- Net insider value flow over the last year: -$491,090.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 24 Insiders of ROCKET PHARMACEUTICALS, INC.
- Symbol
- RCKT, RCKTW on Nasdaq
- Location
- New York, NY
What Changed
- Buy value: $68,500; sell value: $559,590.
- Net share flow: -131,751.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$491,090.
Buys
$68,500
Shares: 20,000
Insiders: 1
Sells
$559,590
Shares: 151,751
Insiders: 7
Net
-$491,090
Shares: -131,751
Insiders: -6
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 33,117 | $0 | $121,231 | -$121,231 |
| 3-6 | 10,000 | 39,811 | $34,400 | $128,053 | -$93,653 |
| 6-9 | 10,000 | 34,055 | $34,100 | $130,205 | -$96,105 |
| 9-12 | 0 | 44,768 | $0 | $180,101 | -$180,101 |
ROCKET PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | Director, Other*, 10%+ Owner | $100,686,510 | Mixed | 19 Sep 2025 | ||
| Roderick Wong | Director, 10%+ Owner | $44,689,444 | Mixed | 18 Jun 2025 | ||
| Gaurav Shah | Ceo | $8,876,477 | -$103,744 | -1.2% | Mixed | 13 May 2026 |
| Kinnari Patel | President, Head of R&D and Chief Operating Officer | $6,417,297 | -$4,944 | -0.08% | Mixed | 20 May 2025 |
| Martin Louis Wilson | General Counsel | $4,472,188 | -$107,385 | -2.3% | Mixed | 13 May 2026 |
| Jonathan David Schwartz | Chief Science & Gene Therapy Officer | $2,692,124 | -$54,011 | -2% | Mixed | 18 Nov 2025 |
| Gotham Makker | Director | $2,545,450 | Mixed | 18 Jun 2025 | ||
| Aaron Ondrey | Chief Financial Officer | $2,394,410 | -$4,257 | -0.18% | Mixed | 03 Jul 2025 |
| Christopher James Stevens | Chief Operating Officer | $1,782,690 | Mixed | 11 Feb 2026 | ||
| Mark Andrew White | General Manager, Commercial Affairs | $1,560,177 | Mixed | 31 Oct 2024 | ||
| Syed Ali-Aamir Rizvi | Chief Medical Officer | $1,549,921 | Mixed | 11 Feb 2026 | ||
| Carlos Garcia-Parada | Chief Financial Officer | $1,068,080 | Mixed | 14 Feb 2022 | ||
| Sarbani Chaudhuri | Chief Commercial & Medical Affairs Officer | $1,026,703 | -$67,741 | -6.2% | Filing P/S | 07 May 2026 |
| John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | $775,128 | -$163,895 | -17% | Mixed | 13 May 2026 |
| Mikael Dolsten | Director | $454,105 | Mixed | 18 Jun 2025 | ||
| Piratip Pratumsuwan | Director | $411,061 | Mixed | 18 Jun 2025 | ||
| Keith Woods | Director | $360,118 | Mixed | 13 Jun 2024 | ||
| David P. Southwell | Director | $354,806 | Mixed | 18 Jun 2025 | ||
| Peter Fong | Director | $174,932 | Mixed | 24 Sep 2025 | ||
| Elisabeth Bjork | Director | $172,000 | +$68,500 | +66% | Filing P/S | 02 Jan 2026 |
| Pedro P. Granadillo | Director | $134,131 | Mixed | 18 Jun 2025 | ||
| Naveen Yalamanchi | Director | $103,965 | Mixed | 13 Jun 2024 | ||
| Carsten Boess | Director | $73,518 | Mixed | 18 Jun 2025 | ||
| Fady Ibraham Malik | Director | $73,518 | Mixed | 18 Jun 2025 |
Top shareholders of ROCKET PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
3/4/5
13F
|
Director, Other*, 10%+ Owner · Company |
—
mixed-class rows
|
21,763,079
mixed-class rows
|
$100,686,510 | — | 19 Sep 2025 | |
| Roderick Wong |
3/4/5
|
Director, 10%+ Owner |
17%
|
18,236,124
|
$44,689,444 | — | 18 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.2%
|
7,834,795
|
$28,048,565 | — | 31 Mar 2026 | |
| CITIGROUP INC |
13F
|
Company |
4.7%
|
5,107,708
|
$18,285,595 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
4.3%
|
4,690,215
|
$16,790,970 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
4.1%
|
4,485,989
|
$16,059,841 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.5%
|
3,775,736
|
$13,517,135 | — | 31 Mar 2026 | |
| MAVERICK CAPITAL LTD |
13F
13D/G
|
Company |
2.3%
from 13D/G
|
3,567,372
|
$12,771,192 | — | 31 Mar 2026 | |
| Newtyn Management, LLC |
13F
|
Company |
2.9%
|
3,165,900
|
$11,333,922 | — | 31 Mar 2026 | |
| Nuveen, LLC |
13F
|
Company |
2.9%
|
3,128,753
|
$11,200,936 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.9%
|
3,118,124
|
$11,162,884 | — | 31 Mar 2026 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.8%
|
3,069,930
|
$10,990,350 | — | 31 Mar 2026 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.8%
|
3,038,715
|
$10,878,600 | — | 31 Mar 2026 | |
| Gaurav Shah |
3/4/5
|
CEO |
—
mixed-class rows
|
2,320,213
mixed-class rows
|
$8,876,477 | -$103,744 | 13 May 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
— |
0.9%
|
1,004,476
|
$7,895,181 | -$48,317,346 | 30 May 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
2,189,256
|
$7,839,361 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
2,169,625
|
$7,767,257 | — | 31 Mar 2026 | |
| Monaco Asset Management SAM |
13F
|
Company |
1.9%
|
2,058,303
|
$7,368,725 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
2,020,108
|
$7,231,988 | — | 31 Mar 2026 | |
| Kinnari Patel |
3/4/5
|
President, Head of R&D and Chief Operating Officer |
—
mixed-class rows
|
745,842
mixed-class rows
|
$6,417,297 | -$4,944 | 20 May 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.6%
|
1,721,116
|
$6,161,594 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
—
mixed-class rows
|
1,302,154
mixed-class rows
|
$4,647,543 | — | 31 Mar 2026 | |
| Martin Louis Wilson |
3/4/5
|
General Counsel |
—
mixed-class rows
|
1,146,826
mixed-class rows
|
$4,472,188 | -$107,385 | 13 May 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1%
|
1,097,623
|
$3,929,490 | — | 31 Mar 2026 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.94%
|
1,023,747
|
$3,665,014 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.93%
|
1,012,126
|
$3,623,411 | — | 31 Mar 2026 | |
| Opaleye Management Inc. |
13F
|
Company |
0.87%
|
955,000
|
$3,418,900 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.79%
|
859,874
|
$3,079,000 | — | 31 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.73%
|
796,224
|
$2,742,991 | — | 31 Mar 2026 | |
| Jonathan David Schwartz |
3/4/5
|
Chief Science & Gene Therapy Officer |
—
mixed-class rows
|
418,746
mixed-class rows
|
$2,692,124 | -$54,011 | 18 Nov 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.66%
|
724,392
|
$2,593,323 | — | 31 Mar 2026 | |
| Gotham Makker |
3/4/5
|
Director |
—
mixed-class rows
|
1,037,149
mixed-class rows
|
$2,545,450 | — | 18 Jun 2025 | |
| Prosight Management, LP |
13F
|
Company |
0.63%
|
683,856
|
$2,448,204 | — | 31 Mar 2026 | |
| Aaron Ondrey |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
262,815
mixed-class rows
|
$2,394,410 | -$4,257 | 03 Jul 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.61%
|
664,821
|
$2,380,059 | — | 31 Mar 2026 | |
| Woodline Partners LP |
13F
|
Company |
0.59%
|
641,222
|
$2,295,575 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.59%
|
640,840
|
$2,294,207 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.58%
|
637,174
|
$2,281,083 | — | 31 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.57%
|
623,354
|
$2,231,607 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.54%
|
590,750
|
$2,114,885 | — | 31 Mar 2026 | |
| Christopher James Stevens |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
562,166
mixed-class rows
|
$1,782,690 | — | 11 Feb 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.44%
|
482,079
|
$1,725,843 | — | 31 Mar 2026 | |
| Jump Financial, LLC |
13F
|
Company |
0.44%
|
476,478
|
$1,705,790 | — | 31 Mar 2026 | |
| FMR LLC |
13F
|
Company |
0.42%
|
462,630
|
$1,656,218 | — | 31 Mar 2026 | |
| Mark Andrew White |
3/4/5
|
General Manager, Commercial Affairs |
—
mixed-class rows
|
101,867
mixed-class rows
|
$1,560,177 | — | 31 Oct 2024 | |
| Syed Ali-Aamir Rizvi |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
500,911
mixed-class rows
|
$1,549,921 | — | 11 Feb 2026 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.38%
|
416,533
|
$1,491,188 | — | 31 Mar 2026 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.35%
|
385,639
|
$1,380,588 | — | 31 Mar 2026 | |
| IEQ CAPITAL, LLC |
13F
|
Company |
0.35%
|
381,839
|
$1,366,984 | — | 31 Mar 2026 | |
| Invesco Ltd. |
13F
|
Company |
0.32%
|
347,543
|
$1,244,203 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for ROCKET PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.49% | $12,120 | $3.61 | -3,361 | 678,639 | 13 May 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.26% | $9,837 | $3.61 | -2,728 | 1,043,327 | 13 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.94% | $3,083 | $3.61 | -855 | 90,164 | 13 May 2026 | Direct |
| Sarbani Chaudhuri | RCKT | Common Stock | Sale | -6.19% | $67,741 | $3.84 | -17,650 | 267,510 | 07 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.26% | $3,862 | $3.34 | -1,157 | 91,019 | 18 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.57% | $19,995 | $3.34 | -5,990 | 1,046,055 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.2% | $4,593 | $3.34 | -1,376 | 682,000 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -1.76% | $40,582 | $3.31 | -12,253 | 683,376 | 13 Feb 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -3.89% | $12,341 | $3.31 | -3,726 | 92,176 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -1.15% | $40,668 | $3.31 | -12,279 | 1,052,045 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Award | 36.8% | 286,028 | 1,064,324 | 11 Feb 2026 | Direct | ||
| Gaurav Shah | RCKT | Stock Option (Right to Buy) | Award | 870,648 | 870,648 | 11 Feb 2026 | Direct | |||
| John Militello | RCKT | Common Stock | Award | 45.5% | 29,982 | 95,902 | 11 Feb 2026 | Direct | ||
| John Militello | RCKT | Stock Option (Right to Buy) | Award | 45,018 | 45,018 | 11 Feb 2026 | Direct | |||
| Martin Louis Wilson | RCKT | Common Stock | Award | 81.2% | 311,813 | 695,629 | 11 Feb 2026 | Direct | ||
| Martin Louis Wilson | RCKT | Stock Option (Right to Buy) | Award | 468,187 | 468,187 | 11 Feb 2026 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 17.9% | 61,963 | 407,874 | 11 Feb 2026 | Direct | ||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Christopher James Stevens | RCKT | Common Stock | Award | 15.2% | 61,963 | 469,129 | 11 Feb 2026 | Direct | ||
| Christopher James Stevens | RCKT | Stock Option (Right to Buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Sarbani Chaudhuri | RCKT | Common Stock | Award | 79.1% | 125,924 | 285,160 | 11 Feb 2026 | Direct | ||
| Sarbani Chaudhuri | RCKT | Stock Option (Right to Buy) | Award | 189,076 | 189,076 | 11 Feb 2026 | Direct | |||
| Elisabeth Bjork | RCKT | Common Stock | Purchase | 25% | $34,400 | $3.44 | 10,000 | 50,000 | 02 Jan 2026 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.84% | $7,592 | $2.98 | -2,545 | 299,064 | 18 Nov 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.62% | $3,240 | $2.98 | -1,086 | 65,920 | 18 Nov 2025 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.8% | $18,721 | $2.98 | -6,276 | 778,296 | 18 Nov 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.43% | $4,910 | $2.98 | -1,646 | 383,816 | 18 Nov 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Award | 35% | 100,000 | 385,462 | 03 Nov 2025 | Direct | ||
| John Militello | RCKT | Common Stock | Sale | -30.2% | $114,581 | $3.96 | -28,918 | 67,006 | 14 Oct 2025 | Direct |
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 345,911 | 345,911 | 06 Oct 2025 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 383,854 | 383,854 | 06 Oct 2025 | Direct | |||
| Peter Fong | RCKT | Common Stock | Award | 53,333 | 53,333 | 24 Sep 2025 | Direct | |||
| Rtw Investments, Lp | RCKT | Common Stock | Other | -5.7% | -1,100,000 | 18,188,457 | 19 Sep 2025 | See footnote | ||
| Rtw Investments, Lp | RCKT | Common Stock | Exercise of in-the-money or at-the-money derivative security | 6.08% | 1,100,000 | 19,188,457 | 19 Sep 2025 | See footnote | ||
| Rtw Investments, Lp | RCKT | Equity Swap (obligation to buy) | Exercise of in-the-money or at-the-money derivative security | -100% | -3 | 0 | 19 Sep 2025 | See footnote | ||
| John Militello | RCKT | Common Stock | Award | 71.5% | 40,000 | 95,924 | 08 Sep 2025 | Direct | ||
| Martin Louis Wilson | RCKT | Common Stock | Award | 110.7% | 150,000 | 285,462 | 08 Sep 2025 | Direct | ||
| Jonathan David Schwartz | RCKT | Common Stock | Award | 36.1% | 80,000 | 301,609 | 08 Sep 2025 | Direct | ||
| Elisabeth Bjork | RCKT | Common Stock | Purchase | 33.3% | $34,100 | $3.41 | 10,000 | 40,000 | 27 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.64% | $1,082 | $3.00 | -361 | 55,924 | 19 Aug 2025 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.36% | $2,412 | $3.00 | -805 | 221,609 | 19 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.43% | $1,762 | $3.00 | -588 | 135,462 | 19 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.23% | $2,142 | $3.06 | -699 | 56,285 | 18 Aug 2025 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.75% | $5,149 | $3.06 | -1,680 | 222,414 | 18 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.73% | $3,077 | $3.06 | -1,004 | 136,050 | 18 Aug 2025 | Direct |
| Gaurav Shah | RCKT | Common Stock | Tax liability | -0.28% | -2,234 | 784,572 | 18 Aug 2025 | Direct | ||
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -4.74% | $33,695 | $3.02 | -11,161 | 224,094 | 14 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -11% | $21,263 | $3.02 | -7,043 | 56,984 | 14 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -8.12% | $36,557 | $3.02 | -12,109 | 137,054 | 14 Aug 2025 | Direct |
| Christopher James Stevens | RCKT | Common Stock | Award | 407,166 | 407,166 | 04 Aug 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.